(R)-4-Methyloxazolidin-2-one → (R)-3-{4-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]-3-methanesulfonylaminophenyl}-4-methyloxazolidin-2-one
반응식
Br[C:2]1[CH:3]=[CH:4][C:5]([C:13]([N:15]2[CH2:20][CH2:19][N:18]([C:21]3[C:26]([CH3:27])=[CH:25][C:24]([CH3:28])=[CH:23][N:22]=3)[CH2:17][CH2:16]2)=[O:14])=[C:6]([NH:8][S:9]([CH3:12])(=[O:11])=[O:10])[CH:7]=1.[CH3:29][C@@H:30]1[CH2:34][O:33][C:32](=[O:35])[NH:31]1>>[CH3:27][C:26]1[C:21]([N:18]2[CH2:19][CH2:20][N:15]([C:13]([C:5]3[CH:4]=[CH:3][C:2]([N:31]4[C@H:30]([CH3:29])[CH2:34][O:33][C:32]4=[O:35])=[CH:7][C:6]=3[NH:8][S:9]([CH3:12])(=[O:11])=[O:10])=[O:14])[CH2:16][CH2:17]2)=[N:22][CH:23]=[C:24]([CH3:28])[CH:25]=1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 1 and using [N-{5-bromo-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}methanesulfonamide (234 mg) described in Preparation Example 123 and (R)-4-methyloxazolidin-2-one (50.6 mg) described in Preparation Example 25, the title compound (20.8 mg) was obtained.